Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols

Mathematical Models and Methods in Applied Sciences

Volumn 9, Issue 4, 1999, Pages 599-615

  Shochat, Eliezer ^a   Hart, Dvora ^b   Agur, Zvia ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033412830     PISSN: 02182025     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0218202599000312     Document Type: Article

References (71)

1. Z. Agur, The effect of drug schedule on responsiveness to chemotherapy, Ann. (N.Y.) Acad. Sci. 504 (1996) 274-277.
2. Z. Agur, R. Arnon and B. Schechter, Reduction of cytotoxicity to normal tissues by new regimens of phase-specific drugs, Math. Biosci. 92 (1988) 1-15.
3. Z. Agur, R. Arnon and B. Schechter, Effect of the dosing interval on survival and myelotoxicity in mice treated by Cytosine arabinoside, Euro. J. Cancer A28 (6/7) (1992) 1085-1090.
4. N. Anderson and J. Lokich, Controversial issues in 5-fluorouracil infusion use. Dose intensity treatment duration, and cost comparisons, Cancer 70 (1992) 998-1002.
5. T. V. Anilkumar, C. E. Sarraf, T. Hunt and M. R. Alison, The nature of cytotoxic drug-induced cell death in murine intestinal crypts, Br. J. Cancer 65 (1992) 552-558.
6. K. Antman et al., A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy, J. Clin. Oncol. 10 (1992) 102-110.
7. C. Arnerlov et al., Mammographic growth rate, DNA ploidy, and S-phase fraction analysis in breast carcinoma. A prognostic evaluation in a screened population, Cancer 70 (1992) 1935-1942.
8. P. Bassa et al., Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer, J. Nucl. Med. 37 (1996) 931-938.
9. E. Belembaogo et al., Neodjuvant chemotherapy in 126 operable breast cancers, Euro. J. Cancer A28 (1992) 896-900.
10. A. H. Calver et al., Carboplatin dosage: prospective evaluation of a simple formula based on renal function, J. Clin. Oncol. 11 (1989) 1748-1756.
11. D. A. Cameron, W. M. Gregory, A. Bowman and R. C. Leonard, Mathematical modelling of tumour response in primary breast cancer, Br. J. Cancer 73 (1996) 1409-1416.
12. L. Cojocaru and Z. Agur, A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs, Math. Biosci. 109 (1992) 85-97.
13. N. G. Davidson, Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience, Semin. Oncol. 23 (1996) 6-10.
14. L. A. Dethlefsen, J. M. S. Prewitt and M. L. Mendelsohn, Analysis of tumor growth curves, J. Natl. Cancer Inst. 40 (1968) 389-405.
15. V. T. DeVita, Jr., The influence of information on drug resistance on protocol design, Ann. Oncol. 2 (1991) 93-106.
16. B. Drewinko, M. Patchen, L. Y. Yang and B. Barlogie, Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells, Cancer Res. 41 (1986) 2328-2333.
17. D. V. Fournier et al., Growth rate of 147 mammary carcinomas, Cancer 45 (1980) 2198-2207.
18. E. Frei, III, Clinical trials of antitumor agents: experimental design and timeline considerations, Cancer J. Sci. Am. 3 (1997) 127-136.
19. E. Fuse, T. Kobayashi, M. Inaba, H. Suzuki and Y. Sugiyama, Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity, J. Natl. Cancer Inst. 86 (1994) 989-996.
20. R. Gilles et al., Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy, Radiology. 191 (1994) 633-638.
21. J. H. Goldie and A. J. Coldman, Mathematic model for relating the drug sensitivity of tumors to their spontaneous mutatuin rate, Cancer Treatment Rep. 63 (1979) 1727-1733.
22. D. Hart, E. Shochat and Z. Agur, The growth law of primary breast cancer as inferred from mammography screening trials data, Br. J. Cancer, in press.
23. J. Herrada et al., Relative value of physical examination, mammography and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in woman receiving neoadjuvant chemotherapy for locally advanced breast carcinoma, Clin. Cancer Res. 3 (1997) 1565-1569.
24. N. H. G. Holford and L. S. Sheiner, Understanding the dose-effect relationship: clinical application of pharmacokinetic - pharmacodynamic models, Clin. Pharmocokin. 6 (1981) 429-453.
25. L. Holmgren, M. S. O'Reilly and J. Folkman, Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nature Med. 1 (1995) 149-153.
26. W. Hryniuk and M. N. Levine. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer, J. Clin. Oncol. 8 (1986) 1162-1170.
27. W. M. Hryniuk, A. Figueredo and M. Goodyear, Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer, Semin. Oncol. 14 (1987) 3-11.
28. C. Hudis et al., Sequential adjuvant therapy: the memorial Sloan-Kettering cancer center experience, Semin. Oncol. 1 (1996) 58-64.
29. D. I. Jodrell et al., Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer, J. Clin. Oncol. 10 (1992) 520-528.
30. D. A. Keefe, R. L. Capizzi and S. A. Rudnick, Methotrexate cytotoxicity for L5178Y/Asn-lymphoblasts: relationship of dose and duration of exposure to tumor cell viability, Cancer Res. 42 (1982) 1641-1645.
31. K. Koda, J. Yasutomi, N. Nakajima, M. McKnight and M. Glassy, Radioimmunoscintigraphy of adenocarcinomas using Monopharm-C, a human monoclonal antibody, conjugated to indium-111, Proc. Am. Soc. Clin. Oncol. 16 (1997) A1545.
32. E. L. Korn and R. Simon, Selecting dose-intense drug combinations: metastatic breast cancer, Br. Cancer Res. Treat. 20 (1992) 155-166.
33. S. Koscielny et al., Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination, Br. J. Cancer 49 (1984) 709-715.
34. A. K. Laird, Dynamics of tumor growth: comparison of growth rates and extrapolation of growth curve to one cell, Br. J. Cancer 20 (1965) 278-291.
35. L. Levin, R. Simon and W. Hryniuk, Importance of multiagent chemotherapy regimens in ovarian carcinoma dose intensity analysis, J. Natl. Cancer Inst. 85 (1993) 1732-1742.
36. J. E. Liebmann et al., Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines, Br. J. Cancer 68 (1993) 1104-1109.
37. H. H. Lloyd, Estimation of tumor cell kill from Gompertz growth curves, Cancer Treat. Rep. 59 (1975) 267-277.
38. J. D. Luketich et al., Comparison of whole body bone scans and positron emission tomography scans for detection of bone metastases in patients with thoracic malignancies, Proc. Am. Soc. Clin. Oncol. 16 (1997) A1521.
39. D. W. Marquardt, An algorithm for least-squares estimation of nonlinear parameters, J. SIAM 2 (1963) 431-441.
40. M. L. Mendelsohn, Cell proliferation and tumour growth, in Cell Proliferation, eds. L. F. Lamberton and R. J. M. Fry RJM (Blackwell, 1963), pp. 498-513.
41. A. A. Miller, M. J. Ratain and R. L. Schilsky, Principles of pharmacology, in The Chemotherapy Source Book, ed. M. C. Perry (Williams & Wilkins, 1996), 2nd edition, pp. 27-41.
42. H. Muss et al., RIA for CA27.29 antigen is highly predictive of relapse in stage II and II breast cancer, Proc. Am. Soc. Clin. Oncol. 157 (1996) A117 (abstract).
43. H. B. Muss et al., c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer, N. Engl. J. Med. 330 (1994) 1260-1266.
44. L. Norton, R. Simon, H. D. Brereton and A. E. Bogden, Measuring the course of gompertzian growth, Nature 264 (1976) 542-545.
45. L. Norton and R. Simon, Tumor size, sensitivity to therapy, and design of treatment schedules, Cancer Treat. Rep. 61 (1977) 1307-1317.
46. L. Norton, A Gompertzian model of human breast cancer growth, Cancer Res. 48 (1988) 7067-7071.
47. L. Norton, Evolving concepts in the systemic drug therapy of breast cancer, Semin. Oncol. 24 (1997) 3-10.
48. S. Ozawa, Y. Sugiyama, J. Mitsuhashi and M. Inaba, Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells, Cancer Res. 49 (1989) 3823-3828.
49. L. A. Perez, D. Dombkowski, J. Efird, F. Preffer and H. D. Suit, Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements, Cancer Res. 55 (1995) 392-398.
50. H. D. Preisler and P. Venugopal, Regrowth resistance in cancer: why has it been largely ignored? Cell Prolif. 28 (1995) 347-356.
51. Y. Remvikos et al., Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy, J. Natl. Cancer Inst. 81 (1989) 1383-1387.
52. C. Rossi et al., Doxorubicin distribution in human breast cancer, Cancer Treat. Rep. 71 (1987) 1221-1226.
53. D. M. F. Savarese, C. C. Hsieh and F. M. Stewart, Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors, J. Clin. Oncol. 15 (1977) 2981.
54. F. M. Schabel, The use of tumor growth kinetics in planning curative chemotherapy of advanced solid tumors, Cancer Res. 29 (1969) 2384-2389.
55. S. M. Scholl et al., Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial, Euro. J. Cancer A30 (1994) 645-652.
56. R. Simon and E. L. Korn, Selecting drug combinations based on total equivalent dose (dose intensity), J. Natl. Cancer Inst. 82 (1990) 1469-1476.
57. I. E. Smith et al., High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer, J. Clin. Oncol. 13 (1995) 424-429.
58. J. S. Spratt and T. L. Spratt, Rates of growth of pulmonary metastases and host survival, Ann. Surgery 159 (1964) 161-171.
59. G. Steel, Cell loss as a factor in the growth of human tumors, Euro. J Cancer 3 (1967) 381-387.
60. R. Taillefer, A. Robidoux, R. Lambert, S. Turpin and J. Laperriere, Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and auxiliary lymph node involvement, J. Nucl. Med. 36 (1995) 1758-1765.
61. I. F. Tannock, Experimental chemotherapy and concepts related to the cell cycle, Internat. J. Radiat. Biol. Rel. Stud. Phys. Chem. Med. 49 (1986) 335-355.
62. I. F. Tannock, The relation between cell proliferation and the vascular system in the transplanted mouse mammary tumour, Br. J. Cancer 22 (1968) 258-273.
63. I. F. Tannock, Population kinetics of carcinoma cells, capillary endothelial cells and fibroblasts in transplanted mouse mammary tumor, Cancer Res. 30 (1970) 2470-2476.
64. C. D. Thron, A possible bias in growth-kinetic estimates of the thickness of the growing layer in multicellular tumor spheroids, Cancer Res. 44(9) (1984) 4208-4210.
65. P. Tracqui, G. C. Cruywagen, D. E. Woodward, G. T. Bartoo, J. D. Murray and E. C. Alvord, Jr., A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth, Cell Prolif. 28 (1995) 17-31.
66. M. Tubiana, M. H. Pejovic, S. Koscielny, N. Chavaudra and E. Malaise, Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer, Internat. J. Cancer 44 (1989) 17-22.
67. P. Ubezio, G. Tagliabue, B. Schechter and Z. Agur, Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics, Cancer Res. 54 (1994) 6446-6451.
68. E. van der Wall, J. H. Beijnen and S. Rodenhuis, High-dose chemotherapy regimens for solid tumors, Cancer Treat. Rev. 21 (1995) 105-132.
69. R. J. Weinkam and D. F. Deen, Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture, Cancer Res. 42 (1982) 1008-1014.
70. G. D. Wilson et al., Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry, Br. J. Cancer 58 (1988) 423-431.
71. H. O. Wintzer, I. Zipfel, J. Schulte-Monting, U. Hellerich and S. von Kleist, Ki-67 immunostaining in human breast tumors and its relationship to prognosis, Cancer 67 (1991) 421-428.